Harrow, Inc. HROW
Set alert
At close · Nov 2
After hours · Nov 2, 4:04 PM ET
- YTD
- -42.45%
- 1 year
- -25.34%
- Open
- 28.38
- Prev close
- 28.24
- Mkt cap
- 1.06B
- Vol
- 742.63K
- Avg vol
- 572.17K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.29
- High
- 28.91
- Forward P/E
- 10.17
- Beta
- 0.17
- Short ratio
- 11.49
- Inst. own
- 58.84%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 32.86
- 200-d avg
- 38.35
- 1y target
- 63.00
1Y chart
Events in this range
- Nov 10, 2025Earnings: 0.03; estimate 0.22; surprise -86.36%
- Mar 2, 2026Earnings: 0.18; estimate 0.4; surprise -55%
- May 11, 2026Earnings: -0.74; estimate -0.43; surprise -72.09%
- May 12, 2026Rating: BTIG · Buy → Buy
- May 13, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Jul 21, 2026Rating: BTIG · Buy → Buy
- Aug 10, 2026Earnings: -0.46; estimate -0.17875; surprise -157.34%
- Aug 11, 2026Rating: BTIG · Buy → Buy
- Sep 9, 2026Rating: Leerink Partners · — → Outperform
- Oct 7, 2026Rating: BTIG · Buy → Buy
Signals (63)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
Newest 20 of 63.
Key statistics
- Market cap
- 1.06B
- Enterprise value
- 1.27B
- Trailing P/E
- 0.00
- Forward P/E
- 10.17
- PEG ratio
- 0.00
- Price / sales
- 3.84
- Price / book
- 69.46
- EPS (TTM)
- -0.99
- Beta
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -13.51%
- Revenue (TTM)
- 275.59M
- Revenue growth
- 10.90%
- Free cash flow
- -5.49M
- Total cash
- 85.32M
- Total debt
- 300.74M
- Return on equity
- -116.07%
- Shares outstanding
- 37.49M
- Short % of float
- 22.19%
- 50-day average
- 32.86
- 200-day average
- 38.35
Analyst view
Consensus: none
- Target (low)
- 45.00
- Target (mean)
- 63.00
- Target (high)
- 88.00
- Strong buy0
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate 0.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | 0.17 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.17875 | -0.46 | -0.28 | -157.34% |
| May 11, 2026 | Mar 31, 2026 | -0.43 | -0.74 | -0.31 | -72.09% |
| Mar 2, 2026 | Dec 31, 2025 | 0.40 | 0.18 | -0.22 | -55.00% |
| Nov 10, 2025 | Sep 30, 2025 | 0.22 | 0.03 | -0.19 | -86.36% |
| Aug 11, 2025 | Jun 30, 2025 | 0.00755 | 0.14 | +0.13 | +1,754.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | BTIG | reit | Buy | Buy |
| Sep 9, 2026 | Leerink Partners | init | — | Outperform |
| Aug 11, 2026 | BTIG | reit | Buy | Buy |
| Jul 21, 2026 | BTIG | reit | Buy | Buy |
| May 13, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| May 12, 2026 | BTIG | reit | Buy | Buy |
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- harrow.com
News
- Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
- PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio
- Harrow Launches HarrowRx Platform
- Harrow's Top Two Drugs Alone Can Justify Its Current Valuation
- Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
- Do Options Traders Know Something About Harrow Stock We Don't?
- Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research
- Harrow Closes Acquisition of TYRVAYA®
- Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
- Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Your note
Sign in to keep a note on HROW — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUM MARK L | Chief Executive Officer | Purchase | May 13, 2026 | 2,996,130 |
| BOLL ANDREW R | President | Purchase | May 13, 2026 | 814,679 |
| GRAVES ADRIENNE L | Director | Purchase | May 17, 2026 | 1,000 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 3, 2026 | 0 |
| SAHAREK JOHN P | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 2, 2025 | 467,388 |
| SHOJAEI AMIR | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.31% | 2,740,117 | 77.27M | Jun 29, 2026 |
| Opaleye Management Inc. | 6.40% | 2,400,000 | 67.68M | Jun 29, 2026 |
| Private Capital Management, LLC | 4.26% | 1,598,770 | 45.09M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.78% | 1,417,212 | 39.97M | Jun 29, 2026 |
| Deep Track Capital, Lp | 2.58% | 969,000 | 27.33M | Jun 29, 2026 |
| State Street Corporation | 2.51% | 939,888 | 26.50M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,001,445 | 28.24M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 836,793 | 23.60M | Sep 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.54% | 576,069 | 16.25M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.25% | 468,451 | 13.21M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.02% | 383,781 | 10.82M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 353,740 | 9.98M | Jul 30, 2026 |